News - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

News


Pharmaceutical Technology Europe
Volume 24, Issue 6

News bites

Novartis takes on UK NHS

The UK's National Health System has cut the cost of treating wet age-related macular degeneration (AMD) by prescribing a cheaper drug over a more expensive one. The controversial element is that the cheaper drug isn't licensed for wet AMD, which has prompted anger from Novartis.
http://PharmTech.com/NovartisUK

Merck job cuts

Merck KGaA has revealed further details about its restructuring programme, including plans to eliminate around 580 jobs. A further 750 positions will be transferred from Switzerland to alternative sites mainly in Germany, the US and China. Among other actions, the company will close its Merck Serono headquarters in Geneva.
http://PharmTech.com/Merckcuts

UK anticounterfeiting

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new anticounterfeiting strategy with the aim of curbing the occurrence of falsified medicines in the county's supply chain. The strategy will focus on prevention, incident management, and investigation of all reports of falsified medicines in the UK.
http://PharmTech.com/UKStrategy

GSK eyes medicines class

GlaxoSmithKline has partnered with the US's Yale university to design a new class of medicines that could be beneficial in areas such as oncology and infection. The collaboration will use proteolysis targeting chimeric molecules, which have the ability to guide proteins to a cell's cleaning mechanism, where they can then be destroyed.
http://PharmTech.com/Class


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here